

Bruno Revol

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8584716/publications.pdf>

Version: 2024-02-01

30
papers

452
citations

759055

12
h-index

752573

20
g-index

37
all docs

37
docs citations

37
times ranked

494
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Facial Paralysis With mRNA COVID-19 Vaccines. <i>JAMA Internal Medicine</i> , 2021, 181, 1243.	2.6	88
2	Diagnosis and management of central sleep apnea syndrome. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 545-557.	1.0	46
3	Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases. <i>Journal of Clinical Epidemiology</i> , 2021, 134, 14-21.	2.4	42
4	Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilanceâ€“pharmacodynamic study. <i>European Respiratory Journal</i> , 2019, 53, 1802472.	3.1	37
5	Impact of concomitant medications on obstructive sleep apnoea. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 688-708.	1.1	31
6	Pharmacokinetic herbâ€“drug interaction between ginger and crizotinib. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1892-1893.	1.1	23
7	Ticagrelor and Centralâ€“Sleep Apnea. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2378-2379.	1.2	21
8	Reported Adverse Drug Reactions Associated With the Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic. <i>Annals of Internal Medicine</i> , 2021, 174, 878-880.	2.0	19
9	Leveraging the Variability of Pharmacovigilance Disproportionality Analyses to Improve Signal Detection Performances. <i>Frontiers in Pharmacology</i> , 2021, 12, 668765.	1.6	19
10	High prevalence of spin was found in pharmacovigilance studies using disproportionality analyses to detect safety signals: a meta-epidemiological study. <i>Journal of Clinical Epidemiology</i> , 2021, 138, 73-79.	2.4	19
11	Who May Benefit From Diuretics in OSA?. <i>Chest</i> , 2020, 158, 359-364.	0.4	17
12	A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases. <i>Journal of Clinical Epidemiology</i> , 2021, 139, 191-198.	2.4	16
13	Baclofen and sleep apnoea syndrome: analysis of VigiBase, the WHO pharmacovigilance database. <i>European Respiratory Journal</i> , 2018, 51, 1701855.	3.1	15
14	Impact of the â€œFrench Levothyrox crisisâ€“on signal detection in the World Health Organization pharmacovigilance database. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1427-1428.	0.9	8
15	Severe central sleep apnoea associated with nalmefene: a case report. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1075-1076.	1.1	5
16	Quantification of Howellâ€“Jolly bodyâ€“like inclusions in ganciclovir toxicity using CellaVision <sc>DM</sc>96 analyser. <i>British Journal of Haematology</i> , 2016, 174, 637-639.	1.2	4
17	What is the best treatment strategy for obstructive sleep apnoea-related hypertension?. <i>Hypertension Research</i> , 2018, 41, 1070-1072.	1.5	4
18	Association between NMDAR antagonists, drug abuse and dependence: A disproportionality analysis from the WHO pharmacovigilance database. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4937-4940.	1.1	4

#	ARTICLE	IF	CITATIONS
19	Severe excessive daytime sleepiness induced by hydroxyurea. <i>Fundamental and Clinical Pharmacology</i> , 2017, 31, 367-368.	1.0	3
20	The avidity of tumor-specific T cells amplified by a plasmacytoid dendritic cell-based assay can predict the clinical evolution of melanoma patients. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 82-94.	1.5	3
21	Use of triptans during pregnancy? With caution!. <i>Therapie</i> , 2019, 76, 477-478.	0.6	3
22	Gabapentinoids and sleep apnea syndrome: a safety signal from the WHO pharmacovigilance database. <i>Sleep</i> , 2019, 42, .	0.6	3
23	Proton pump inhibitors and Raynaud's phenomenon: is there a link?. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2443-2444.	1.1	2
24	Diuretics in Obstructive Sleep Apnea Patients with Concomitant Hypertension. <i>Annals of the American Thoracic Society</i> , 2021, 18, 2101-2102.	1.5	2
25	Valproic acid and sleep apnoea: A disproportionality signal from the WHO pharmacovigilance database. <i>Respirology</i> , 2020, 25, 336-338.	1.3	2
26	Deprescribing antihypertensive drugs after starting OSA primary therapy?. <i>Sleep</i> , 2022, , .	0.6	2
27	Drugs and obstructive sleep apnoea. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2317-2318.	1.1	1
28	Baclofen, insomnia and sleep apnea: a dangerous triad?. <i>Sleep Medicine</i> , 2021, 79, 224.	0.8	1
29	Immunoglobulins: Benefits and risks from the patient's point of view. <i>Therapie</i> , 2017, 72, 683-684.	0.6	0
30	Impact of OSA primary therapy on antihypertensive drugs use. <i>Sleep</i> , 0, , .	0.6	0